ERBB2 and cancer: We have developed an immunoPET tracer utilizing a radiolabeled antibody to IFNγ to monitor response to cancer immunotherapy, and we previously demonstrated that anti-IFNγ PET can identify HER2 cancer vaccine-induced intratumoral immune activation (26).